• Emergence of new variants & resurgence of cases suggest that the pandemic far from over: Army Chief General Manoj Mukund Naravane
  • Active COVID-19 cases in country decline to 95,014: Union Health Ministry
  1. You Are At:
  2. English News
  3. India
  4. COVID-19: Sputnik V roll out delayed in Delhi

COVID-19: Sputnik V roll out delayed in Delhi

A spokesperson of Apollo Hospitals said the facility in Delhi will tentatively start administering 2-dose vaccine by June 25.

New Delhi Published on: June 20, 2021 13:53 IST
COVID-19, Sputnik V, roll out delayed, Delhi, coronavirus pandemic, covid latest news, corona update

Sputnik V roll out delayed in Delhi.


The roll out of Russian COVID-19 vaccine Sputnik V at Indraprastha Apollo and Madhukar Rainbow Children's Hospital in Delhi has been delayed for some days, officials said on Sunday.

A spokesperson of Apollo Hospitals said the facility in Delhi will tentatively start administering the two-dose vaccine by June 25.

An official had earlier said the hospital would start giving Sputnik V jabs by June 20.

According to an official of Madhukar Rainbow Children's Hospital, there is a delay on the part of the suppliers.

"We are expecting (roll out) next week," he said.

Fortis Healthcare, which had said it would make Sputnik V available at its Gurgaon and Mohali hospitals from Saturday, also has not started administering the Russian vaccine so far.

"The roll out did not happen on Saturday. We expect there will be some clarity on Monday," an official said.

The Centre has fixed the price of the vaccine at Rs 1,145 per dose. The maximum price of Covishield for private COVID-19 Vaccination Centres (CVCs) has been fixed at Rs 780 per dose, while that of Covaxin is Rs 1,410 per dose.

Russia's Gamaleya National Research Institute of Epidemiology and Microbiology has developed Sputnik V and the Russian Direct Investment Fund (RDIF) is marketing it globally.

Hyderabad-based Dr Reddy's Laboratories, the marketing partner for the vaccine in the country, has been importing the shots from Russia.

Over a period of time, the vaccine is also going to be manufactured in India.
Sputnik V uses two different viruses that cause the common cold (adenovirus) in humans. It employs a different vector for each of the two shots, given 21 days apart.

According to Gamaleya and the RDIF, Sputnik V has demonstrated an efficacy rate of 92 per cent.

Also Read: Sputnik V to offer booster shot to other manufacturers, adjusted to work against Delta variant

Also Read: CoWIN, Aarogya Setu, Paytm: How to register for Covishield, Covaxin, Sputnik vaccination

Latest India News

Write a comment